Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.

MLA

Iwasa, Motoh, et al. “Effectiveness of 1-Year Pemafibrate Treatment on Steatotic Liver Disease: The Influence of Alcohol Consumption.” European Journal of Gastroenterology & Hepatology, vol. 36, no. 6, June 2024, pp. 793–801. EBSCOhost, https://doi.org/10.1097/MEG.0000000000002766.

APA

Iwasa, M., Sugimoto, R., Eguchi, A., Tamai, Y., Shigefuku, R., Fujiwara, N., Tanaka, H., Kobayashi, Y., Ikoma, J., Kaito, M., & Nakagawa, H. (2024). Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption. European Journal of Gastroenterology & Hepatology, 36(6), 793–801. https://doi.org/10.1097/MEG.0000000000002766

Chicago

Iwasa, Motoh, Ryosuke Sugimoto, Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Naoto Fujiwara, Hideaki Tanaka, et al. 2024. “Effectiveness of 1-Year Pemafibrate Treatment on Steatotic Liver Disease: The Influence of Alcohol Consumption.” European Journal of Gastroenterology & Hepatology 36 (6): 793–801. doi:10.1097/MEG.0000000000002766.